NCT01805518View on ClinicalTrials.gov

Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Adverse Mental/Physical Effects of Low Dose S. Tortuosum.
Interventions
DIETARY_SUPPLEMENT

Scelectium Tortuosum

"One arm has subjects 3 weeks on Scelectium Tortuosum 25gm po/d then 3 weeks off and then 3 weeks on Placebo.~The other arm has subjects 3 weeks on placebo, then 3 weeks off and then 3 weeks on Scelectium Tortuosum 25mg po/d."

Trial Locations (1)

00918

Michel A. Woodbury, MD, San Juan

All Listed Sponsors
collaborator

PL Thomas & Co., Inc.

INDUSTRY

lead

Woodbury, Michel, M.D.

INDIV

NCT01805518 - Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals | Biotech Hunter | Biotech Hunter